Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Hauser DN, Hastings TG
Hims & Hers
Here are the highlights from the large-scale study: The test subjects included 1900 patients, all of whom had body-mass indexes of over 30, meaning they qualified as clinically obese Each participant received either 2.4 mg of semaglutide injected subcutaneously (under the skin) or a placebo The trial lasted over a year At the end of the trial, the patients who received semaglutide experienced a 14.9% loss in excess body weight
BPC-157 is not covered by insurance -- it's a cash-pay peptide therapy ($250/month at Moonshot Medical)
US$ 21.32
US$ 25.76
US$ 28.23
US$ 26.16
US$ 24.91
US$ 22.59
US$ 27.47
US$ 20.30
US$ 28.64
US$ 20.94
